mfn-cus-2022

Nanologica Publishes Prospectus in Connection with Preferential Rights Issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Nanologica AB (publ) ("Nanologica" or the Company") announced on 23 August 2022 that the Board of Directors has resolved

Read more »

Bulletin from the Extraordinary General Meeting of Nanologica AB (publ)

Nanologica AB (publ) held an extraordinary general meeting, where the following resolutions were passed. Resolution regarding approval of the board of directors’ resolution to issue shares with preferential rights for existing shareholders In accordance with previously announced information, the board of directors on August 23, 2022, resolved to issue new shares with preferential rights for the shareholders, subject to the extraordinary general meeting's subsequent approval. The general meeting resolved, with the required majority, to approve

Read more »

Nanologica Receives Order for Silica for Preparative Chromatography

Nanologica AB (publ) has taken an order for the company's silica for preparative chromatography at a value of approximately MSEK 1.3. The order comes from Nanologica's partner in China, Yunbo Technology (Beijing) Co. Ltd. In July 2019, Nanologica signed an agreement with Chinese Yunbo Technology for the supply of silica for preparative chromatography worth approximately MUSD 14 (currently equivalent to approximately MSEK 150), between 2021 and 2026. The order that has now been placed is

Read more »

Nanologica to Execute a Preferential Rights Issue of up to MSEK 94 to Intensify Efforts within Chromatography

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Nanologica AB (publ) ("Nanologica" or the Company") resolved today, 23 August 2022, to carry out a rights issue of

Read more »

Nanologica’s Interim Report Jan – Jun 2022

FINANCIAL SUMMARY Net sales for the quarter amounted to TSEK 210 (4,497) and for the half-year to TSEK 479 (10,119) The operating result for the quarter amounted to TSEK -12,397 (-8,094) and for the half-year to TSEK -27,989 (-14,862) Result after tax for the quarter amounted to TSEK -13,473 (-9,216) and for the half-year to TSEK -29,388 (-17,061) Earnings per share before and after dilution were SEK -0.48 (-0.33) for the quarter and SEK -1.04

Read more »

Nanologica Takes Order from Insulin Manufacturer for Production

Nanologica AB (publ) has taken an order for the company's silica for preparative chromatography for evaluation in production scale, from one of the world's largest manufacturers of insulin. If the products meet the customer's expectations, Nanologica expects commercial deliveries within a year. Nanologica has been working with customers within preparative chromatography since 2016 and several customers have successfully evaluated the company's silica for preparative chromatography, NLAB Saga®, in various stages. Nanologica has been collaborating with

Read more »